# Relievant Medsystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/relievant-medsystems

- Industry: Medical Devices & Equipment
- Headquarters: Edina, US
- Website: www.relievant.com
- Total disclosed funding: $210M
- Latest round: Series G (Mar 20, 2023)
- Investors on record: 15

## About

Relievant Medsystems, Inc. is a US-based medical technology company focused on providing innovative treatments for vertebrogenic low back pain through its minimally invasive Intracept Procedure.Founded in 2006 in Edina, US, Relievant Medsystems, Inc. specializes in addressing chronic low back pain with its Intracept Procedure. The CEO, Art Taylor, leads the company following its recent acquisition by Boston Scientific Corporation on September 19, 2023, for USD 850.00 mn, allowing Boston Scientific to enhance its chronic pain portfolio. Relievant has completed a total of 11 deals, demonstrating significant business activity since its inception.Relievant's primary offering is the Intracept Procedure, a minimally invasive treatment for patients suffering from vertebrogenic low back pain. This procedure employs targeted radiofrequency energy to disrupt pain signaling, addressing the root causes of the condition. Supported by three clinical trials, it has shown substantial improvements in pain levels for chronic low back pain patients. The company serves a diverse client base, including healthcare providers in pain management, orthopedics, and neurology across North America, Europe, and select Asian markets.Relievant generates revenue through the Intracept Procedure, collaborating with healthcare facilities and practitioners. The company’s revenue model involves direct transactions with hospitals, which bill insurers for the procedure, ensuring patient access. Pricing varies by region and facility, reflecting operational costs and reimbursement rates, with the Intracept Procedure positioned as a primary solution for chronic low back pain management.Following the acquisition finalized on September 19, 2023, Relievant Medsystems, Inc. plans to leverage its new partnership with Boston Scientific Corporation to further integrate the Intracept system into broader pain management strategies. The acquisition funding of USD 850.00 mn will support development initiatives and market expansion efforts, allowing Relievant to enhance its offerings and reach new geographic markets.

## Funding rounds

- Series G, Mar 20, 2023, $46M — Morgenthaler Ventures, New Enterprise Associates, Canaan Partners, Endeavour Vision, Lightstone Ventures, Ally Bridge Group, Vensana Capital
- Series E, Jun 26, 2018, $58M — Morgenthaler Ventures, New Enterprise Associates, Canaan Partners, Richard King Mellon Foundation, Endeavour Vision, Emergent Medical Ventures
- Series D, Aug 26, 2016, $22M — Morgenthaler Ventures, New Enterprise Associates, Canaan Partners, Emergent Medical Ventures
- Series D, Mar 29, 2012, $30M — Morgenthaler Ventures, New Enterprise Associates, Canaan Partners, ONSET Ventures, Emergent Medical Ventures
- Series C, Apr 28, 2009, $20M — Morgenthaler Ventures, Canaan Partners, ONSET Ventures, Emergent Medical Ventures
- Series B, Apr 4, 2008, $4M — Canaan Partners, ONSET Ventures, BCM Technologies
- Series B, Jun 26, 2006, $5M — Canaan Partners, ONSET Ventures, BCM Technologies
- Series B, Nov 4, 2004, $25M — Enterprise Partners Venture Capital, Oak Investment Partners, Montlake Capital, Wall Street Technology Partners

## Investors

- Enterprise Partners Venture Capital (https://capitalatlas.ai/funds/enterprise-partners-venture-capital) — Series B
- Oak Investment Partners (https://capitalatlas.ai/funds/oak-investment-partners) — Series B
- Montlake Capital (https://capitalatlas.ai/funds/montlake-capital) — Series B
- Wall Street Technology Partners (https://capitalatlas.ai/funds/wall-street-technology-partners) — Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C, Series D, Series E, Series G
- ONSET Ventures (https://capitalatlas.ai/funds/onset-ventures) — Series B, Series C, Series D
- BCM Technologies — Series B
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series C, Series D, Series E, Series G
- Emergent Medical Ventures (https://capitalatlas.ai/funds/emergent-medical-ventures) — Series C, Series D, Series E
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series D, Series E, Series G
- Richard King Mellon Foundation — Series E
- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series E, Series G
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series G
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series G
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series G